Thomas Kelly Jr
Concepts (333)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Serine Endopeptidases | 11 | 2016 | 52 | 2.040 |
Why?
| Gelatinases | 11 | 2016 | 32 | 2.020 |
Why?
| Membrane Proteins | 16 | 2023 | 342 | 1.870 |
Why?
| Breast Neoplasms | 14 | 2024 | 1169 | 1.500 |
Why?
| Neoplasm Invasiveness | 9 | 2016 | 268 | 0.930 |
Why?
| Glucuronidase | 5 | 2010 | 46 | 0.880 |
Why?
| Students, Medical | 1 | 2023 | 159 | 0.770 |
Why?
| Neoplasms | 4 | 2023 | 1233 | 0.620 |
Why?
| Neoplasm Metastasis | 8 | 2011 | 231 | 0.600 |
Why?
| Endopeptidases | 13 | 2016 | 67 | 0.590 |
Why?
| Adenocarcinoma | 3 | 2005 | 401 | 0.560 |
Why?
| Proteoglycans | 5 | 2023 | 80 | 0.480 |
Why?
| Animals | 30 | 2023 | 13150 | 0.480 |
Why?
| Extracellular Matrix | 6 | 2005 | 111 | 0.470 |
Why?
| Syndecan-1 | 4 | 2010 | 72 | 0.470 |
Why?
| Medical Oncology | 2 | 2023 | 96 | 0.460 |
Why?
| Cell Movement | 4 | 2019 | 247 | 0.450 |
Why?
| Cell Line, Tumor | 10 | 2020 | 1402 | 0.440 |
Why?
| Disease | 1 | 2012 | 25 | 0.400 |
Why?
| Cellular Microenvironment | 1 | 2012 | 26 | 0.400 |
Why?
| Cocaine | 2 | 2023 | 169 | 0.390 |
Why?
| Cell Membrane | 9 | 2005 | 248 | 0.380 |
Why?
| Cell Cycle Proteins | 3 | 2020 | 166 | 0.380 |
Why?
| Vulvar Neoplasms | 3 | 2016 | 52 | 0.380 |
Why?
| Humans | 44 | 2024 | 49827 | 0.380 |
Why?
| Mice | 11 | 2023 | 5720 | 0.370 |
Why?
| Fructose | 1 | 2010 | 23 | 0.370 |
Why?
| Antigens, Neoplasm | 2 | 2011 | 151 | 0.370 |
Why?
| Dipeptidyl Peptidase 4 | 3 | 2011 | 10 | 0.370 |
Why?
| Carbon | 1 | 2010 | 55 | 0.360 |
Why?
| Stromal Cells | 3 | 2016 | 72 | 0.360 |
Why?
| Cytoskeletal Proteins | 3 | 2020 | 49 | 0.340 |
Why?
| Dopaminergic Neurons | 3 | 2023 | 18 | 0.330 |
Why?
| Membrane Glycoproteins | 6 | 2005 | 240 | 0.330 |
Why?
| Neovascularization, Pathologic | 3 | 2005 | 161 | 0.330 |
Why?
| Multiple Myeloma | 6 | 2004 | 2910 | 0.330 |
Why?
| Bone and Bones | 2 | 2010 | 468 | 0.320 |
Why?
| Carcinoma, Squamous Cell | 3 | 2016 | 319 | 0.320 |
Why?
| Heparan Sulfate Proteoglycans | 2 | 2005 | 11 | 0.310 |
Why?
| Mammary Neoplasms, Experimental | 2 | 2005 | 122 | 0.300 |
Why?
| Female | 22 | 2024 | 26329 | 0.300 |
Why?
| Osteogenesis | 1 | 2010 | 351 | 0.300 |
Why?
| Tumor Cells, Cultured | 7 | 2010 | 465 | 0.290 |
Why?
| Cell Adhesion | 7 | 2020 | 158 | 0.290 |
Why?
| RNA, Messenger | 4 | 2023 | 1105 | 0.290 |
Why?
| Osteoclasts | 1 | 2010 | 425 | 0.290 |
Why?
| Bone Resorption | 2 | 2010 | 304 | 0.290 |
Why?
| Bone Neoplasms | 2 | 2005 | 179 | 0.270 |
Why?
| Mice, SCID | 4 | 2010 | 175 | 0.260 |
Why?
| Oligosaccharides | 1 | 2005 | 32 | 0.260 |
Why?
| Schizosaccharomyces | 1 | 2006 | 54 | 0.260 |
Why?
| Antibodies, Neoplasm | 1 | 2005 | 28 | 0.260 |
Why?
| Peripheral Nerves | 2 | 2015 | 51 | 0.250 |
Why?
| Education, Medical, Undergraduate | 1 | 2006 | 82 | 0.250 |
Why?
| Nanostructures | 1 | 2005 | 47 | 0.250 |
Why?
| Pseudohypoaldosteronism | 1 | 2024 | 5 | 0.240 |
Why?
| Receptors, Mineralocorticoid | 1 | 2024 | 9 | 0.240 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 829 | 0.240 |
Why?
| Extinction, Psychological | 1 | 2023 | 31 | 0.230 |
Why?
| Metalloendopeptidases | 3 | 1998 | 70 | 0.220 |
Why?
| gamma-Aminobutyric Acid | 1 | 2023 | 64 | 0.220 |
Why?
| Research | 1 | 2023 | 112 | 0.220 |
Why?
| Actins | 5 | 2020 | 118 | 0.220 |
Why?
| Fear | 1 | 2023 | 81 | 0.210 |
Why?
| Biomedical Research | 1 | 2006 | 231 | 0.210 |
Why?
| Serotonin | 1 | 2023 | 151 | 0.210 |
Why?
| Cell Proliferation | 5 | 2019 | 1007 | 0.210 |
Why?
| Parkinson Disease, Secondary | 1 | 2021 | 7 | 0.200 |
Why?
| Program Evaluation | 1 | 2023 | 349 | 0.200 |
Why?
| Drug-Seeking Behavior | 1 | 2021 | 5 | 0.200 |
Why?
| Pyrans | 1 | 2021 | 22 | 0.200 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2021 | 23 | 0.200 |
Why?
| Cues | 1 | 2021 | 49 | 0.190 |
Why?
| Collagenases | 2 | 1999 | 25 | 0.190 |
Why?
| Reinforcement Schedule | 1 | 2021 | 78 | 0.190 |
Why?
| Receptor, Cannabinoid, CB2 | 1 | 2021 | 58 | 0.190 |
Why?
| Neoplasm Proteins | 4 | 1998 | 323 | 0.190 |
Why?
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2020 | 4 | 0.190 |
Why?
| Radial Artery | 1 | 2020 | 31 | 0.180 |
Why?
| Curriculum | 1 | 2023 | 404 | 0.180 |
Why?
| Pyrimidines | 1 | 2021 | 191 | 0.180 |
Why?
| Pyridines | 1 | 2021 | 130 | 0.180 |
Why?
| Behavior, Animal | 1 | 2021 | 182 | 0.180 |
Why?
| Collagen Type I | 2 | 2016 | 89 | 0.180 |
Why?
| Cyclin-Dependent Kinase 5 | 1 | 2020 | 1 | 0.180 |
Why?
| Actin Cytoskeleton | 1 | 2020 | 22 | 0.180 |
Why?
| Matrix Metalloproteinases | 1 | 2000 | 48 | 0.180 |
Why?
| Neurons | 1 | 2023 | 459 | 0.180 |
Why?
| Cyclic AMP | 1 | 2020 | 90 | 0.170 |
Why?
| Immunohistochemistry | 5 | 2016 | 971 | 0.170 |
Why?
| Lung Neoplasms | 1 | 2005 | 605 | 0.170 |
Why?
| Parkinson Disease | 1 | 2021 | 152 | 0.170 |
Why?
| Cocaine-Related Disorders | 1 | 2021 | 205 | 0.170 |
Why?
| Cell Division | 3 | 2004 | 292 | 0.160 |
Why?
| Pancreas | 1 | 2019 | 71 | 0.160 |
Why?
| Mice, Inbred BALB C | 2 | 2011 | 303 | 0.150 |
Why?
| Cell Transformation, Neoplastic | 1 | 2019 | 177 | 0.150 |
Why?
| Phenotype | 3 | 2010 | 727 | 0.150 |
Why?
| Carcinoma, Ductal, Breast | 1 | 1998 | 89 | 0.150 |
Why?
| Protein Processing, Post-Translational | 1 | 2019 | 171 | 0.150 |
Why?
| Coronary Artery Disease | 1 | 2020 | 274 | 0.140 |
Why?
| Phosphorylation | 3 | 2020 | 536 | 0.140 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2016 | 47 | 0.130 |
Why?
| Scavenger Receptors, Class A | 1 | 2016 | 39 | 0.130 |
Why?
| Cell Transformation, Viral | 3 | 1994 | 25 | 0.130 |
Why?
| Fibroma | 1 | 2015 | 39 | 0.130 |
Why?
| Syndecans | 4 | 2005 | 34 | 0.130 |
Why?
| Avian Sarcoma Viruses | 2 | 1994 | 5 | 0.130 |
Why?
| Enzyme Activation | 3 | 2006 | 276 | 0.120 |
Why?
| Neoplasm Transplantation | 2 | 2005 | 85 | 0.120 |
Why?
| Fibroblasts | 3 | 1994 | 343 | 0.120 |
Why?
| Transplantation, Heterologous | 2 | 2005 | 74 | 0.120 |
Why?
| Extracellular Matrix Proteins | 2 | 1994 | 69 | 0.120 |
Why?
| Transfection | 3 | 2004 | 357 | 0.120 |
Why?
| Neoplasm Recurrence, Local | 2 | 2015 | 618 | 0.120 |
Why?
| Peptide Hydrolases | 2 | 1994 | 62 | 0.120 |
Why?
| Cytoskeleton | 3 | 1989 | 39 | 0.110 |
Why?
| Macrophages | 1 | 2016 | 364 | 0.110 |
Why?
| Aged, 80 and over | 5 | 2020 | 3125 | 0.110 |
Why?
| Wnt1 Protein | 1 | 2012 | 10 | 0.110 |
Why?
| Ventral Tegmental Area | 2 | 2023 | 7 | 0.110 |
Why?
| Mammary Neoplasms, Animal | 1 | 2012 | 35 | 0.110 |
Why?
| Phytotherapy | 1 | 2012 | 44 | 0.110 |
Why?
| Cadherins | 3 | 2016 | 68 | 0.110 |
Why?
| Interleukin-8 | 2 | 2010 | 87 | 0.100 |
Why?
| Chick Embryo | 5 | 1999 | 83 | 0.100 |
Why?
| Serine Proteinase Inhibitors | 1 | 2012 | 9 | 0.100 |
Why?
| Organ Specificity | 1 | 2012 | 108 | 0.100 |
Why?
| Male | 7 | 2024 | 25093 | 0.100 |
Why?
| Signal Transduction | 6 | 2020 | 1617 | 0.090 |
Why?
| Microscopy, Phase-Contrast | 1 | 2010 | 11 | 0.090 |
Why?
| Rats | 3 | 2023 | 3300 | 0.090 |
Why?
| Plant Lectins | 1 | 2010 | 8 | 0.090 |
Why?
| PAX2 Transcription Factor | 1 | 2010 | 22 | 0.090 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2012 | 181 | 0.090 |
Why?
| Culture Media, Conditioned | 1 | 2010 | 48 | 0.090 |
Why?
| Carcinoma, Papillary | 1 | 2010 | 48 | 0.090 |
Why?
| Glycosylation | 1 | 2010 | 100 | 0.090 |
Why?
| Substrate Specificity | 1 | 2010 | 195 | 0.090 |
Why?
| Insulin | 1 | 2012 | 457 | 0.090 |
Why?
| Carcinoma, Renal Cell | 1 | 2010 | 106 | 0.090 |
Why?
| Acoustics | 1 | 2009 | 32 | 0.090 |
Why?
| Magnetics | 1 | 2009 | 39 | 0.090 |
Why?
| Light | 1 | 2009 | 70 | 0.090 |
Why?
| Kidney Neoplasms | 1 | 2010 | 178 | 0.080 |
Why?
| Neoplastic Cells, Circulating | 1 | 2009 | 73 | 0.080 |
Why?
| Neoplasm Staging | 3 | 2016 | 746 | 0.080 |
Why?
| Aged | 7 | 2020 | 9272 | 0.080 |
Why?
| Protein Structure, Tertiary | 3 | 2005 | 253 | 0.080 |
Why?
| Diet | 1 | 2012 | 564 | 0.080 |
Why?
| Mesoderm | 1 | 2008 | 27 | 0.080 |
Why?
| Early Detection of Cancer | 1 | 2009 | 165 | 0.080 |
Why?
| Muscle, Smooth | 1 | 1987 | 63 | 0.080 |
Why?
| Disease Models, Animal | 2 | 2021 | 1451 | 0.080 |
Why?
| Integrins | 3 | 2016 | 31 | 0.070 |
Why?
| DNA, Mitochondrial | 1 | 2008 | 112 | 0.070 |
Why?
| Glycoproteins | 1 | 1987 | 115 | 0.070 |
Why?
| Middle Aged | 7 | 2020 | 11997 | 0.070 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 595 | 0.070 |
Why?
| Epithelial Cells | 1 | 2008 | 209 | 0.070 |
Why?
| Breast | 2 | 2016 | 85 | 0.070 |
Why?
| Blotting, Western | 3 | 2012 | 602 | 0.070 |
Why?
| DNA, Complementary | 2 | 2004 | 135 | 0.070 |
Why?
| Dimerization | 1 | 2006 | 53 | 0.070 |
Why?
| Catalytic Domain | 1 | 2006 | 57 | 0.070 |
Why?
| Lymphatic Metastasis | 2 | 2015 | 230 | 0.070 |
Why?
| E-Selectin | 1 | 2005 | 15 | 0.070 |
Why?
| Schizosaccharomyces pombe Proteins | 1 | 2006 | 39 | 0.070 |
Why?
| Protein Kinases | 1 | 2006 | 72 | 0.070 |
Why?
| Pancreatic Neoplasms | 1 | 2008 | 213 | 0.070 |
Why?
| Metals | 1 | 2005 | 34 | 0.060 |
Why?
| Chi-Square Distribution | 2 | 2016 | 282 | 0.060 |
Why?
| Phototherapy | 1 | 2005 | 45 | 0.060 |
Why?
| Ligands | 1 | 2005 | 204 | 0.060 |
Why?
| Immunoblotting | 2 | 2003 | 118 | 0.060 |
Why?
| Time Factors | 3 | 2015 | 2912 | 0.060 |
Why?
| Fungal Proteins | 1 | 2006 | 124 | 0.060 |
Why?
| Heparitin Sulfate | 1 | 2004 | 8 | 0.060 |
Why?
| Carcinogens | 2 | 2005 | 199 | 0.060 |
Why?
| Fibronectins | 2 | 1998 | 39 | 0.060 |
Why?
| Career Choice | 1 | 2006 | 111 | 0.060 |
Why?
| Models, Biological | 2 | 2005 | 728 | 0.060 |
Why?
| Matrix Metalloproteinase 9 | 3 | 2002 | 86 | 0.060 |
Why?
| Growth Substances | 2 | 2003 | 23 | 0.060 |
Why?
| Hyperthermia, Induced | 1 | 2005 | 118 | 0.060 |
Why?
| Antibodies, Monoclonal | 3 | 2023 | 458 | 0.060 |
Why?
| Gold | 1 | 2005 | 135 | 0.060 |
Why?
| Osteolysis | 1 | 2004 | 75 | 0.060 |
Why?
| Microfilament Proteins | 2 | 2020 | 43 | 0.060 |
Why?
| Microscopy, Fluorescence | 2 | 2003 | 162 | 0.060 |
Why?
| Odds Ratio | 2 | 2015 | 548 | 0.060 |
Why?
| Receptors, Lipoprotein | 1 | 2003 | 7 | 0.060 |
Why?
| Cells, Cultured | 4 | 2016 | 1571 | 0.060 |
Why?
| Gene Deletion | 1 | 2024 | 266 | 0.060 |
Why?
| Lipoproteins, HDL | 1 | 2003 | 18 | 0.060 |
Why?
| Receptors, Immunologic | 1 | 2003 | 37 | 0.060 |
Why?
| Vimentin | 2 | 2016 | 32 | 0.050 |
Why?
| Chondroitin Sulfate Proteoglycans | 1 | 2023 | 19 | 0.050 |
Why?
| Nitric Oxide Synthase | 1 | 2003 | 75 | 0.050 |
Why?
| Eukaryotic Cells | 1 | 2003 | 17 | 0.050 |
Why?
| Oligonucleotides, Antisense | 1 | 2003 | 28 | 0.050 |
Why?
| Blotting, Northern | 1 | 2003 | 109 | 0.050 |
Why?
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2023 | 24 | 0.050 |
Why?
| Cloning, Molecular | 1 | 2003 | 189 | 0.050 |
Why?
| Treatment Outcome | 3 | 2020 | 5138 | 0.050 |
Why?
| Cell Separation | 1 | 2003 | 88 | 0.050 |
Why?
| Logistic Models | 2 | 2015 | 891 | 0.050 |
Why?
| Mucous Membrane | 1 | 2002 | 28 | 0.050 |
Why?
| Models, Genetic | 1 | 2003 | 174 | 0.050 |
Why?
| Molecular Weight | 3 | 1994 | 84 | 0.050 |
Why?
| Tumor Microenvironment | 1 | 2024 | 210 | 0.050 |
Why?
| Rectum | 1 | 2002 | 54 | 0.050 |
Why?
| Oxidopamine | 1 | 2021 | 4 | 0.050 |
Why?
| Rats, Long-Evans | 1 | 2021 | 26 | 0.050 |
Why?
| Up-Regulation | 1 | 2023 | 450 | 0.050 |
Why?
| Bone Marrow | 1 | 2003 | 362 | 0.050 |
Why?
| Estradiol | 1 | 2003 | 225 | 0.050 |
Why?
| Adult | 5 | 2016 | 13160 | 0.050 |
Why?
| Carcinoma | 1 | 2003 | 137 | 0.050 |
Why?
| Endothelium, Vascular | 1 | 2003 | 254 | 0.050 |
Why?
| Self Administration | 1 | 2021 | 101 | 0.050 |
Why?
| Neuronal Plasticity | 1 | 2021 | 58 | 0.050 |
Why?
| Retrospective Studies | 3 | 2020 | 6117 | 0.050 |
Why?
| Biopsy | 2 | 2015 | 582 | 0.050 |
Why?
| Gene Expression Regulation | 1 | 2005 | 979 | 0.050 |
Why?
| Neuroprotective Agents | 1 | 2021 | 105 | 0.050 |
Why?
| Australia | 1 | 2020 | 83 | 0.050 |
Why?
| Actin Depolymerizing Factors | 1 | 2020 | 5 | 0.040 |
Why?
| Thiazolidines | 1 | 2020 | 5 | 0.040 |
Why?
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2020 | 20 | 0.040 |
Why?
| Flow Cytometry | 1 | 2003 | 470 | 0.040 |
Why?
| Propensity Score | 1 | 2020 | 124 | 0.040 |
Why?
| Recombinant Proteins | 2 | 2016 | 486 | 0.040 |
Why?
| Stress Fibers | 1 | 2019 | 5 | 0.040 |
Why?
| Collagen | 2 | 1998 | 206 | 0.040 |
Why?
| HEK293 Cells | 1 | 2020 | 222 | 0.040 |
Why?
| Focal Adhesion Kinase 1 | 1 | 2019 | 15 | 0.040 |
Why?
| HeLa Cells | 1 | 2020 | 251 | 0.040 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2019 | 50 | 0.040 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2019 | 51 | 0.040 |
Why?
| Platelet-Derived Growth Factor | 1 | 2019 | 23 | 0.040 |
Why?
| Evaluation Studies as Topic | 1 | 1999 | 106 | 0.040 |
Why?
| Gene Expression Profiling | 1 | 2003 | 1031 | 0.040 |
Why?
| Pseudopodia | 1 | 1998 | 4 | 0.040 |
Why?
| Bone Remodeling | 1 | 2000 | 149 | 0.040 |
Why?
| RNA, Small Interfering | 1 | 2019 | 215 | 0.040 |
Why?
| Prostatic Neoplasms | 1 | 2002 | 396 | 0.040 |
Why?
| Thiophenes | 1 | 1998 | 36 | 0.040 |
Why?
| Linear Models | 1 | 1999 | 281 | 0.040 |
Why?
| Survival Rate | 1 | 2020 | 905 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 1 | 2021 | 1374 | 0.040 |
Why?
| Phenylalanine | 1 | 1998 | 128 | 0.040 |
Why?
| Databases, Factual | 1 | 2020 | 664 | 0.040 |
Why?
| Antineoplastic Agents | 1 | 2005 | 1172 | 0.040 |
Why?
| Infant, Newborn | 1 | 2024 | 2744 | 0.040 |
Why?
| Risk Factors | 2 | 2015 | 3619 | 0.040 |
Why?
| Lymph Nodes | 1 | 1998 | 264 | 0.030 |
Why?
| Enzyme Inhibitors | 1 | 1998 | 391 | 0.030 |
Why?
| Young Adult | 2 | 2015 | 3936 | 0.030 |
Why?
| Anion Exchange Protein 1, Erythrocyte | 1 | 2015 | 8 | 0.030 |
Why?
| Antiporters | 1 | 2015 | 19 | 0.030 |
Why?
| beta Catenin | 1 | 2016 | 102 | 0.030 |
Why?
| Mice, Inbred C57BL | 2 | 2016 | 1806 | 0.030 |
Why?
| S100 Proteins | 1 | 2015 | 34 | 0.030 |
Why?
| Antigens, CD | 1 | 2016 | 215 | 0.030 |
Why?
| Neoplasm, Residual | 1 | 2015 | 166 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2015 | 585 | 0.030 |
Why?
| Protease Inhibitors | 1 | 1994 | 58 | 0.030 |
Why?
| Mutation | 1 | 2019 | 1293 | 0.030 |
Why?
| Disease Progression | 1 | 2015 | 822 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 143 | 0.030 |
Why?
| Lactation | 1 | 2012 | 62 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 181 | 0.030 |
Why?
| Cell Nucleus | 2 | 2010 | 184 | 0.030 |
Why?
| Melanoma | 1 | 1994 | 284 | 0.020 |
Why?
| Mice, Transgenic | 1 | 2012 | 555 | 0.020 |
Why?
| Cross Reactions | 2 | 1987 | 41 | 0.020 |
Why?
| Rheology | 1 | 2009 | 7 | 0.020 |
Why?
| Molecular Mimicry | 1 | 2009 | 38 | 0.020 |
Why?
| Matrix Metalloproteinase 2 | 2 | 2002 | 57 | 0.020 |
Why?
| Receptors, Transforming Growth Factor beta | 1 | 2008 | 25 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2010 | 854 | 0.020 |
Why?
| Nanoparticles | 1 | 2009 | 145 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2010 | 904 | 0.020 |
Why?
| Microscopy, Electron | 1 | 1987 | 77 | 0.020 |
Why?
| Transforming Growth Factor beta | 1 | 2008 | 144 | 0.020 |
Why?
| Chickens | 1 | 1987 | 106 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1036 | 0.020 |
Why?
| Kidney | 1 | 2010 | 665 | 0.020 |
Why?
| Fibroblast Growth Factor 2 | 1 | 2005 | 34 | 0.020 |
Why?
| Pregnancy | 1 | 2012 | 2584 | 0.020 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2005 | 201 | 0.020 |
Why?
| Scavenger Receptors, Class B | 1 | 2003 | 10 | 0.010 |
Why?
| Receptors, Scavenger | 1 | 2003 | 29 | 0.010 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2003 | 66 | 0.010 |
Why?
| Hormone Replacement Therapy | 1 | 2003 | 27 | 0.010 |
Why?
| Spectrin | 1 | 1982 | 3 | 0.010 |
Why?
| Ovariectomy | 1 | 2003 | 119 | 0.010 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2003 | 78 | 0.010 |
Why?
| Brain Chemistry | 1 | 1982 | 70 | 0.010 |
Why?
| Vasodilation | 1 | 2003 | 97 | 0.010 |
Why?
| Femoral Artery | 1 | 2003 | 100 | 0.010 |
Why?
| Protein Transport | 1 | 2003 | 179 | 0.010 |
Why?
| Endoscopy | 1 | 2002 | 124 | 0.010 |
Why?
| Neutrophils | 1 | 2002 | 137 | 0.010 |
Why?
| Sex Factors | 1 | 2003 | 693 | 0.010 |
Why?
| Mice, Knockout | 1 | 2003 | 841 | 0.010 |
Why?
| beta 2-Microglobulin | 1 | 1997 | 38 | 0.010 |
Why?
| Rhodamines | 1 | 1993 | 5 | 0.010 |
Why?
| Cell Adhesion Molecules | 1 | 1994 | 85 | 0.010 |
Why?
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 1993 | 12 | 0.010 |
Why?
| Gelatin | 1 | 1993 | 25 | 0.010 |
Why?
| Biotin | 1 | 1993 | 45 | 0.010 |
Why?
| Binding Sites | 1 | 1993 | 377 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 1993 | 587 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 1993 | 797 | 0.010 |
Why?
| Talin | 1 | 1989 | 3 | 0.010 |
Why?
| Concanavalin A | 1 | 1989 | 11 | 0.010 |
Why?
| Microspheres | 1 | 1989 | 25 | 0.010 |
Why?
| Cell Line, Transformed | 1 | 1989 | 72 | 0.010 |
Why?
| Protein Binding | 1 | 1989 | 660 | 0.000 |
Why?
| Vinculin | 1 | 1982 | 3 | 0.000 |
Why?
| Actinin | 1 | 1982 | 2 | 0.000 |
Why?
| Immune Sera | 1 | 1982 | 17 | 0.000 |
Why?
| Erythrocyte Membrane | 1 | 1982 | 14 | 0.000 |
Why?
| Ankyrins | 1 | 1982 | 9 | 0.000 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 1982 | 103 | 0.000 |
Why?
| Fluorescent Antibody Technique | 1 | 1982 | 108 | 0.000 |
Why?
| Epitopes | 1 | 1982 | 59 | 0.000 |
Why?
| Cattle | 1 | 1982 | 210 | 0.000 |
Why?
| Terminology as Topic | 1 | 1982 | 63 | 0.000 |
Why?
| Swine | 1 | 1982 | 391 | 0.000 |
Why?
| Muscle Proteins | 1 | 1982 | 303 | 0.000 |
Why?
|
|
Kelly Jr's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|